TEVA PHARMA
Teva Pharma provides the development, manufacturing, and sales of pharmaceutical services.
TEVA PHARMA
Social Links:
Industry:
Manufacturing Pharmaceutical Quality Assurance
Founded:
2016-04-01
Address:
Nagoya, Aichi, Japan
Country:
Japan
Website Url:
http://www.takeda-teva.com
Total Employee:
101+
Status:
Active
Contact:
81 3-6459-3066
Similar Organizations
Aspiro Pharma
Aspiro Pharma offers research, development, and manufacturing of pharmaceutical products.
Concord Biotech
Concord Biotech provides the development, manufacturing and commercialization of a variety of biopharmaceutical products.
Cronus Pharma Specialties India private limited Ltd
Cronus is engaged in the development, manufacturing and sale of generic veterinary pharmaceutical products.
Jazeera Pharmaceuticals Industries
Jazeera Pharmaceuticals Industries is engages in the research, development, manufacture, and marketing of pharmaceutical products.
Jerusalem Pharmaceuticals
Jerusalem Pharmaceuticals core business is the development, manufacturing and marketing of pharmaceutical products.
Stedman Pharmaceuticals
Stedman Pharmaceuticals provides manufacturing and marketing of pharmaceutical formulations.
Current Employees Featured
Official Site Inspections
http://www.takeda-teva.com Semrush global rank: 517.17 K Semrush visits lastest month: 65.24 K
- Host name: sinai.co.jp
- IP address: 153.149.182.99
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Teva Pharma"
Takeda and Teva Establish "Teva Takeda Yakuhin Ltd." in Japan
Apr 1, 2016 Osaka, Japan and Jerusalem, April 1, 2016 – Takeda Pharmaceutical Company Limited (TSE: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) …See details»
About us | Takeda U.S.
We are focused on creating better health for people and a brighter future for the world. We aim to discover and deliver lifetransforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, …See details»
武田テバ（武田テバファーマ株式会社 : 武田テバ薬品 …
武田テバは、日本における武田薬品の企業ブランドや強固な流通網と、テバが有する開発、製造から提供までの仕組みや世界規模の事業基盤、研究開発における専門知識とを組み合わせることにより、数多くの患者さんに貢献するビジネ …See details»
会社概要 | 武田テバについて | 武田テバ（武田テバファーマ株式 …
武田テバ薬品株式会社 (Teva Takeda Yakuhin Ltd.) , 所在地 東京都渋谷区恵比寿四丁目20番3号 恵比寿ガーデンプレイスタワー18階, 代表者の役職・氏名 代表取締役社長兼CEO 豊原 善弘, …See details»
武田テバについて | 武田テバ（武田テバファーマ株式 …
武田テバは、ジェネリック医薬品と新薬を取り扱う武田テバファーマ株式会社と、武田薬品から継承した長期収載品を取り扱う武田テバ薬品株式会社の2社で構成しています。武田テバは、2016年4月より国内外のグローバル製薬企業の …See details»
Our Management | Corporate Goverance | Takeda
The Company established Takeda Executive Team (TET) consists of the President & CEO and function heads of the Takeda Group in order to ensure the agility and flexibility of business execution and deeper cooperation among the …See details»
Teva Announces New Organization Structure and Leadership …
Kåre Schultz, Teva’s President and CEO, said, “Teva is taking decisive and immediate action to address external pressures and internal inefficiencies. Our new company structure will enable …See details»
Teva Takeda Pharma - Crunchbase Company Profile & Funding
Organization. Teva Takeda Pharma . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Teva Takeda Pharma is a pharmaceutical …See details»
Teva Announces New Organizational Structure and ... - Teva …
Jun 2, 2014 About Teva. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by …See details»
Japan: Teva Divests Takeda Joint Venture; Astellas …
Dec 16, 2024 Teva-Takeda is a joint venture established in 2016 by Japanese drugmaker Takeda and Teva, focusing primarily on the business of generic and off-patent medicines. ... The World Health Organization listed KM Biologics’ …See details»
Teva Announces Agreement to Divest Teva-Takeda, its Business …
Dec 5, 2024 Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which …See details»
Teva Announces New Organizational Structure and Senior …
Jun 2, 2014 Mr. Drapé, had served until this position as the Head of Sterile, Respiratory and Specialty Operations in the Teva's Global Operations organization (TGO). He joined Teva in …See details»
About Our Company | Takeda Pharmaceuticals
Our vision is to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. This purpose-led and values-based approach is a core …See details»
Teva and Takeda form new company to develop generic …
Apr 3, 2016 Takeda Japan pharma business unit president Masato Iwasaki said: "Takeda’s leading brand reputation and strong distribution presence in Japan combined with Teva’s …See details»
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025
19 hours ago Net income attributable to Teva and diluted earnings per share in the first quarter of 2025 were $214 million and $0.18, respectively, compared to net loss attributable to Teva …See details»
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 …
1 day ago Net income attributable to Teva and diluted earnings per share in the first quarter of 2025 were $214 million and $0.18, respectively, compared to net loss attributable to Teva and …See details»
社長メッセージ | 武田テバについて | 武田テバ（武田テバファー …
社長メッセージ. 2016年の設立以来、武田テバファーマ及び武田テバ薬品はジェネリック医薬品と長期収載品の提供を通じて、医療関係者の皆さまに必要な安全性・有効性の情報をお届け …See details»
Teva, Takeda offload generics, manufacturing plant to Nichi-Iko in ...
Jul 30, 2020 Teva and Takeda's Japanese venture will offload most of its generics portfolio and a manufacturing site to Nichi-Iko Pharmaceutical as the partners "shift focus" to a smaller core …See details»
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 …
20 hours ago On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues …See details»
Takeda Pharmaceuticals: Global Homepage
Mar 3, 2025 Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera. March 3, 2025. View All. We exist to …See details»